ADRB2 and nonpapillary renal cell carcinoma: Propranolol and ICI-118,551 have shown antitumor benefits in VHL-derived ccRCC, and since ccRCCs comprise 75% of the total RCCs, targeting ADRB-2 becomes a promising drug for VHL and other non-VHL tumors.